REFERENCES
1. Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br J Haematol 2016;172:512-23.
2. Vichinsky E, Neumayr L, Trimble S, et al. CDC Thalassemia Investigators. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion 2014;54:972-81; quiz 971.
3. Marsella M, Ricchi P. Thalassemia and hepatocellular carcinoma: links and risks. J Blood Med 2019;10:323-34.
4. Mancuso A. Evidence-based medicine and management of hepatocellular carcinoma in Thalassemia. BMC Gastroenterol 2020;20:409.
5. Mangia A, Bellini D, Cillo U, et al. Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. BMC Gastroenterol 2020;20:251.
6. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
7. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021;73 Suppl 1:4-13.
8. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol 2020;72:250-61.
9. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6.
10. Cancer stat facts: liver and intrahepatic bile duct cancer. Available from: https://seer.cancer.gov/statfacts/html/livibd.html [Last accessed on 25 Nov 2021].
11. Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004;124:114-7.
12. Borgna-Pignatti C, Garani MC, Forni GL, et al. Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol 2014;167:121-6.
13. Kourakli A, Diamantidis MD, Skafidas M, et al. Hepatitis C virus infection, but not hepatic iron overload is the dominant risk factor for the manifestation of hepatocellular carcinoma among Greek thalassemic patients. Blood 2018;132:2347.
14. Fragatou S, Tsourveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit. Hemoglobin 2010;34:221-6.
15. Papadopoulos N, Kountouras D, Malagari K, Tampaki M, Theochari M, Koskinas J. Characteristics and prognosis of hepatocellular carcinoma in multi-transfused patients with β-thalassemia. Experience of a single tertiary center. Mediterr J Hematol Infect Dis 2020;12:e2020013.
16. Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin 2006;30:119-24.
17. De Sanctis V, Soliman AT, Daar S, et al. A concise review on the frequency, major risk factors and surveillance of hepatocellular carcinoma (HCC) in β-thalassemias: past, present and future perspectives and the ICET-A experience. Mediterr J Hematol Infect Dis 2020;12:e2020006.
18. Mancuso A. Hepatocellular carcinoma in thalassemia: a critical review. World J Hepatol 2010;2:171-4.
19. Finianos A, Matar CF, Taher A. Hepatocellular carcinoma in β-thalassemia patients: review of the literature with molecular insight into liver carcinogenesis. Int J Mol Sci 2018;19:4070.
20. Aydinok Y, Porter JB, Piga A, et al. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. Eur J Haematol 2015;95:244-53.
21. Pok S, Barn VA, Wong HJ, et al. Testosterone regulation of cyclin E kinase: a key factor in determining gender differences in hepatocarcinogenesis. J Gastroenterol Hepatol 2016;31:1210-9.
22. Akinyemiju T, Abera S, Ahmed M, et al. Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-91.
23. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52.
24. Huang YT, Jen CL, Yang HI, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011;29:3643-50.
25. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1.
26. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016;64:800-6.
27. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006;28:126-35.
28. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol 2012;4:74-80.
29. European Association for the Study of the Liver, Electronic address: [email protected], European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.
30. Di Marco V, Capra M, Gagliardotto F, et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica 2008;93:1243-6.
31. Triantos C, Kourakli A, Kalafateli M, et al. Hepatitis C in patients with β-thalassemia major. A single-centre experience. Ann Hematol 2013;92:739-46.
32. Alavian SM, Tabatabaei SV, Kamran BL. Epidemiology of HCV infection among thalassemia patients in eastern Mediterranean countries: a quantitative review of literature. Iran Red Crescent Med J 2010;12:365-76.
33. Koike K. Pathogenesis of HCV-associated HCC: dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling. Hepatol Res 2007;37 Suppl 2:S115-20.
34. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007;22 Suppl 1:S108-11.
35. Origa R, Ponti ML, Filosa A, et al. Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE). Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. Am J Hematol 2017;92:1349-55.
36. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009;50:1142-54.
37. Association for the Study of the Liver, Electronic address: [email protected], Clinical Practice Guidelines Panel: Chair:, EASL Governing Board representative, Panel members. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J Hepatol 2020;73:1170-218.
38. Sinakos E, Kountouras D, Koskinas J, et al. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease. Br J Haematol 2017;178:130-6.
39. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153:996-1005.e1.
41. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007;5:938-45, 945.e1.
42. Tarao K, Nozaki A, Ikeda T, et al. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 2019;8:1054-65.
43. Li CK, Chik KW, Lam CW, et al. Liver disease in transfusion dependent thalassaemia major. Arch Dis Child 2002;86:344-7.
44. European Association for the Study of the Liver, Electronic address: [email protected]., European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
45. Colli A, Nadarevic T, Miletic D, et al. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346.
46. Bradbear RA, Bain C, Siskind V, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 1985;75:81-4.
47. Elmberg M, Hultcrantz R, Ekbom A, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733-41.
48. Sharp P, Srai SK. Molecular mechanisms involved in intestinal iron absorption. World J Gastroenterol 2007;13:4716-24.
49. Kountouras D, Tsagarakis NJ, Fatourou E, et al. Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection. Liver Int 2013;33:420-7.
50. Siagris D, Giannakoulas N, Christofidou M, et al. Virological, immunological and histological aspects in adult beta-thalassemic patients with chronic hepatitis C virus infection. Liver Int 2004;24:204-9.
51. Maira D, Cassinerio E, Marcon A, et al. Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT). Ann Hematol 2017;96:1931-6.
52. Delicou S, Maragkos K, Tambaki M, Kountouras D, Koskinas J. Transient elastography (TE) is a useful tool for assessing the response of liver iron chelation in sickle cell disease patients. Mediterr J Hematol Infect Dis 2018;10:e2018049.
53. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17-21.
54. Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med 2020;52:1898-907.
55. Fargion S, Valenti L, Fracanzani AL. Role of iron in hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2014;3:108-10.
56. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149:1060-72.
59. Deugnier Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology 2011;141:1202-11, 1211.e1-3.
60. Kato J, Miyanishi K, Kobune M, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007;42:830-6.
61. Ba Q, Hao M, Huang H, et al. Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin Cancer Res 2011;17:7625-33.
62. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-61.
63. Porter J, Viprakasit V, Kattamis A. . Chapter 3: Iron overload and chelation. Guidelines for the management of transfusion dependent thalassaemia (TDT). Nicosia (CY): Thalassaemia International Federation; 2014.
64. Cata JP, Wang H, Gottumukkala V, Reuben J, Sessler DI. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth 2013;110:690-701.
65. Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: a comprehensive review. Cancer 2017;123:751-8.
66. Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit 2003;9:RA19-22.
67. Shen L, Zhou Y, He H, et al. Crosstalk between macrophages, T Cells, and iron metabolism in tumor microenvironment. Oxid Med Cell Longev 2021;2021:8865791.
68. Asare GA, Bronz M, Naidoo V, Kew MC. Synergistic interaction between excess hepatic iron and alcohol ingestion in hepatic mutagenesis. Toxicology 2008;254:11-8.
69. Sekine S, Ito K, Watanabe H, et al. Mitochondrial iron accumulation exacerbates hepatic toxicity caused by hepatitis C virus core protein. Toxicol Appl Pharmacol 2015;282:237-43.
70. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011;55:920-32.
